论文部分内容阅读
目的了解吡嗪酰胺对肺结核合并糖尿病患者高尿酸血症的发生率及严重程度。方法选取2013年1月~2015年12月本院确诊的60例糖尿病合并肺结核患者(观察组)以及60例非糖尿病肺结核患者(对照组),对两组高尿酸血症发生率、严重程度及相关因素进行对比观察。结果观察组总的高尿酸血症发生率为65%,对照组总的高尿酸血症发生率为30%,两组高尿酸血症发生率比较差异有统计学意义(P<0.05),观察组重度高尿酸血症发生率较对照组明显增高(P<0.05);观察组出现高尿酸血症的时间比对照组要早(P<0.05),症状消失时间晚(P<0.05)。结论糖尿病合并肺结核患者服用吡嗪酰胺后高尿酸血症的发生率更高,发生时间早,症状消失时间长,在今后的临床工作中要引起重视,及时监测、及时处理,避免严重并发症的发生。
Objective To investigate the incidence and severity of pyrazinamide on hyperuricemia in patients with pulmonary tuberculosis complicated with diabetes mellitus. Methods Sixty patients with diabetes mellitus complicated with pulmonary tuberculosis (observation group) and 60 patients with non-diabetic pulmonary tuberculosis (control group) diagnosed in our hospital from January 2013 to December 2015 were selected. The incidence and severity of hyperuricemia Related factors for comparative observation. Results The total incidence of hyperuricemia was 65% in the observation group and 30% in the control group. There was significant difference in the incidence of hyperuricemia between the two groups (P <0.05) The incidence of severe hyperuricemia was significantly higher than that of the control group (P <0.05). The duration of hyperuricemia in the observation group was earlier than that in the control group (P <0.05), and the disappearance of symptoms was late (P <0.05). Conclusion The incidence of hyperuricemia in patients with diabetes mellitus and pulmonary tuberculosis after taking pyrazinamide is higher, and the occurrence time is earlier and symptoms disappear for a long time. In the future clinical work, attention should be paid to timely monitoring and timely treatment to avoid serious complications occur.